Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | LSS | P48449 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4544705 | 0.91 | HRH3 (0.66) | HRH3KDM4EALDH1A1SMN1; SMN2KEAP1 | |
| SCHEMBL678570 | 0.83 | HRH3 (0.56) | HRH3KDM4ELTA4HCYP1A2CYP2D6 | |
| SCHEMBL9671156 | 0.83 | KDM4E (0.83) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL1908631 | 0.82 | LTA4H (0.50) | KDM4EALDH1A1SMN1; SMN2LTA4HCYP1A2 | |
| SCHEMBL12775992 | 0.81 | CHRNB2 (0.53) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL12359378 | 0.80 | HRH3 (0.73) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL13958920 | 0.80 | HRH3 (0.63) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL3260775 | 0.79 | HRH3 (0.71) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL110784 | 0.79 | KEAP1 (0.83) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL679055 | 0.79 | KDM4E (0.65) | HRH3KDM4EALDH1A1SMN1; SMN2LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | HRH3 485/4885KDM4E 2789/4885ALDH1A1 749/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | HRH3 707/4885KDM4E 3026/4885ALDH1A1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.